Despite changes, generics continue to face obstacles in Japan

05/21/2013 | BioSpectrum Asia

Although Japan is the world's second-largest pharmaceutical market after the U.S., generics represent only 6.6% of prescription drug sales, largely because of public attitudes skeptical of the effectiveness and safety of unfamiliar brands, especially if the drugs are produced in countries such as India and China. Several factors may help change these views: government efforts to further cut generic-drug prices, higher reimbursements for generics, patent expirations and a rapidly aging population.

View Full Article in:

BioSpectrum Asia

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD